WALTHAM, Mass.--(BUSINESS WIRE)--
NeuroMetrix, Inc. (Nasdaq: NURO) reported today that the United States
Patent and Trademark Office has issued a Notice of Allowance for a
patent application covering unique aspects of the Company's wearable
pain relief technology. The patent addresses an important element in the
Company proprietary OptiTherapy™ technology that automatically controls
nerve stimulation to optimize pain relief. In particular, the patent
covers the automated calibration procedure that determines the
appropriate stimulation level for each device user. The Company expects
the patent to issue in mid-2015 and to extend patent protection into
2032. The technology is incorporated in the currently marketed
prescription SENSUS® pain management device and in Quell™
which will be unveiled at the International Consumer Electronics Show
(CES) in Las Vegas in January 2015.
Quell™ utilizes NeuroMetrix's proprietary non-invasive neurostimulation
technology to provide relief from chronic pain, particularly neuropathic
pain such as due to diabetes and lower back problems. The advanced
wearable device is lightweight and can be worn during the day while
active, and at night while sleeping. It has been cleared by the FDA for
treatment of chronic pain without a prescription. Users of the device
will also have the option of using their smartphone to automatically
track and personalize their pain therapy. The Company expects Quell™ to
be available for purchase by consumers in the second quarter of 2015.
About NeuroMetrix
NeuroMetrix is an innovative health-care company that develops wearable
medical technology and point-of-care tests that help patients and
physicians better manage chronic pain, nerve diseases, and sleep
disorders. For more information, please visit http://www.NeuroMetrix.com.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
News Provided by Acquire Media
